GlassScriptPhysician profile
Mary D Altmeyer
NPI 1144493024
$8,961.32
in general payments reported to CMS, 2019-2025
18 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,545 · 2020: $250 · 2021: $2,114 · 2022: $679 · 2023: $452 · 2024: $764 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338 · Education: $35.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.99 |
| Education | $35.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $5,671.96 | 2019-2025 | Valchlor |
| Abbvie INC. | $917.91 | 2019-2024 | |
| Kyowa Kirin, INC. | $379.91 | 2022-2025 | Poteligeo |
| Janssen Scientific Affairs, LLC | $306.61 | 2019-2024 | Tremfya |
| Genzyme Corporation | $255.88 | 2024 | |
| Lilly USA, LLC | $218.20 | 2019-2020 | |
| Ucb, INC. | $217.94 | 2019-2023 | Bimzelx |
| Dermavant Sciences, INC. | $125.00 | 2023 | Vtama |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Vyne Pharmaceuticals INC. | $124.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.93 | 2023 | Sotyktu |
| Galderma Laboratories, L.P. | $117.99 | 2019 | |
| Journey Medical Corporation | $111.25 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.13 | 2019 | |
| Revance Therapeutics, INC. | $73.29 | 2025 | Daxxify |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $41.96 | 2024 | Benchmark Ultra |
| Novartis Pharmaceuticals Corporation | $31.37 | 2024 | |
| Sun Pharmaceutical Industries INC. | $25.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Altmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.